The purpose of this funding opportunity announcement (FOA) is to support the development of new therapeutic approaches for individuals with Opioid Use Disorder (OUD) and co-occurring mental disorders (COMD). Research applications may include the development of new chemical entities, new lead compounds, repurposed marketed medications, new formulations of existing medications, new behavioral therapies, therapeutic devices, and digital therapeutics. The COMD comorbid with OUD may include anxiety disorders, mood disorders, impulse control disorders, attention deficit disorders, schizophrenia, and others https://www.nimh.nih.gov/health/topics/substance-use-and-mental-health.
This funding opportunity utilizes the UG3/UH3 Phased Innovation Awards Cooperative Agreement grant mechanism that includes two phases. The applications responding to this FOA should present a research plan that will cover both the UG3 and UH3 phases. In the UG3 phase is for up to 2 years and the project will have a set of milestones to be completed by the end of this period. Once the UG3 phase has been successfully completed, the project may transition to the UH3 phase and may be funded for up to three additional years.